PATENT CLAIM ANALYSIS

Application Number: 16324365
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["435", "006140"]

Abstract:
The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.

Claim (Index 24):
The method of  claim 23 , wherein the plurality of probes further comprises a third locus specific probe comprising\n a third target specific region complementary to a third target nucleic acid sequence at Chr7: 5532143-5532217 in the ACTB gene, wherein the third target nucleic acid sequence does not contain a recognition site for the methylation-sensitive restriction enzyme; and wherein the third locus specific probe is detectably labelled.

Metadata:
- Claim Count in Document: 58.0
- Percentile: 99.0
- Lexical Diversity: 1.16667
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15300399', '10971339', '12476981', '11518353', '14775876']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5871523916031057
- 35 USC 102 Novelty (BERT): 0.523450275872108
- Combined Prediction Score: 0.580782180030006
- Mean Citation Score: 321.436012
- Max Citation Score: 329.37662
- Similarity Product: 249.3883698042667

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test